What are the recommended dosing regimens for first‑line and adjunctive vasopressors in adult patients with hypotension or shock?

Vasopressor Dosing in Adult Hypotension and Shock

Norepinephrine is the first-line vasopressor for adult patients with hypotension or shock, targeting an initial mean arterial pressure (MAP) of 65 mmHg, with vasopressin 0.03 units/minute added as a second-line agent when additional blood pressure support is needed. 1

First-Line Vasopressor: Norepinephrine

The Surviving Sepsis Campaign guidelines establish norepinephrine as the first-choice vasopressor with strong recommendation and moderate quality evidence 1. This recommendation is reinforced by the 2018 international consensus, which identifies norepinephrine as first-line therapy across most shock states due to its reliable vasoconstrictor effects with minimal chronotropic impact 2.

Dosing approach:

• Start norepinephrine early when MAP falls below 65 mmHg despite adequate fluid resuscitation
• Titrate to achieve MAP target of 65 mmHg initially 1
• Consider higher MAP targets (70-80 mmHg) in patients with chronic hypertension, though this requires individualization based on perfusion markers
• Doses can be escalated up to ≥1 µg/kg/min in refractory cases, though adding second-line agents is preferred at lower thresholds 3

Second-Line Vasopressor: Vasopressin

When norepinephrine alone is insufficient, add vasopressin at a fixed dose of 0.03 units/minute 1. This recommendation carries weak to moderate quality evidence but is consistently endorsed across guidelines.

Key dosing principles for vasopressin:

• Fixed dose of 0.03 units/minute (do not titrate) 1
• Add when norepinephrine requirements reach 0.25-0.50 µg/kg/min, typically after 2-6 hours of norepinephrine alone 4
• Never use vasopressin as monotherapy for initial vasopressor support 1
• Doses above 0.03-0.04 units/minute should be reserved only for salvage therapy when other agents have failed 1
• The intent is either to raise MAP to target or to reduce norepinephrine requirements (norepinephrine-sparing effect) 2, 1

Third-Line Option: Epinephrine

If MAP remains inadequate despite norepinephrine plus vasopressin, add epinephrine or substitute it for norepinephrine 1. This carries weak recommendation with low quality evidence. Epinephrine can be titrated to effect, though specific dosing ranges are not rigidly defined in guidelines.

Alternative Agents (Highly Restricted Use)

Dopamine: Only consider in highly selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia 1. This is a weak recommendation with low quality evidence. Never use low-dose dopamine for renal protection (strong recommendation, high quality evidence) 1.

Phenylephrine: Not recommended except in three specific circumstances 1:

• Norepinephrine causes serious arrhythmias
• Cardiac output is known to be high with persistently low blood pressure
• Salvage therapy when combined inotrope/vasopressor drugs and low-dose vasopressin have failed

Inotropic Support: Dobutamine

For patients with persistent hypoperfusion despite adequate fluid loading and vasopressor use, add dobutamine up to 20 µg/kg/min 1. This addresses myocardial dysfunction when present. Dobutamine remains the first-line inotrope when myocardial function is depressed 2.

Critical Monitoring and Titration Principles

• Place an arterial catheter as soon as practical in all patients requiring vasopressors 1
• Titrate vasopressors to the minimal efficacious dose 2
• Wean vasopressors as promptly as possible when hemodynamics stabilize 2
• When weaning combination therapy (norepinephrine + vasopressin), taper based on MAP response; 88% of clinicians use MAP level to trigger tapering, with 89% using progressive discontinuation 4

Common Pitfalls to Avoid

Do not delay norepinephrine initiation. Early administration achieves MAP targets faster and may reduce fluid overload risk 3. The diastolic arterial pressure can help identify patients needing urgent norepinephrine 3.

Do not exceed vasopressin 0.03-0.04 units/minute except in salvage situations, as higher doses increase risk of complications including mesenteric and digital ischemia 1.

Do not use vasopressin as monotherapy for initial treatment of sepsis-induced hypotension 1.

Avoid excessive vasoconstriction by monitoring perfusion markers beyond blood pressure alone, as vasopressors have a narrow therapeutic window 2.